Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement therapies for serious medical conditions associated with lost or dysfunctional cells. Its AlloSCOPE platform uses pluripotent cells to produce differentiated, allogeneic replacement cells for transplantation. The pipeline includes OpRegen, an RPE cell therapy for geographic atrophy secondary to dry age-related macular degeneration, developed with Roche and Genentech; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ReSonance, an auditory neuron progenitor cell transplant in preclinical development with William Demant Invest 2 Aps; and research programs in islet cells, photoreceptor cells and other cell transplants. Lineage develops and manufactures its cell candidates and advances some programs itself while seeking collaborations or partnerships for others. It also provides clinical, technical, training, manufacturing and procurement services to Genentech in support of OpRegen. Its corporate headquarters are in Carlsbad, California, and its cGMP cell manufacturing facility is in Israel.
No SEC Form 4 filings for $LCTX in the last 30 days.
See all $LCTX insider activity →Lineage Cell Therapeutics (LCTX) reported Q3 2026 revenue decline and wider operating loss, with non-cash warrant remeasurement affecting net income. The company acquired HUNT1 through the NeuroAirmid acquisition, extending its cash runway into Q2 2028.
Lineage Cell Therapeutics, Inc. (LCTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Acquired NeuroAirmid Therapeutics, Inc. and Its Cell Therapy Product Candidate for Huntington’s Disease, Currently Enrolling in a Phase 1b/2a Clinical Trial (REGEN4H
Lineage Cell Therapeutics (LCTX) reported Q3 2026 net income of $4.2M, reversing a $29.8M loss from Q3 2025. The company attributed the improvement to non-cash warrant remeasurement. Lineage also acquired NeuroAirmid, adding the clinical-stage HUNT1 to its pipeline. The acquisition expands Lineage's clinical-stage pipeline, with key catalysts including HUNT1 development and COR1 preclinical data expected in Q1 2027.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning LCTX (Lineage Cell Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 3 bearish.
Recent LCTX coverage spans earnings, financial news and technology.
Earnings miss and higher loss likely weigh on the stock, though the acquisition may provide upside if integration succeeds.
Acquisition expands pipeline and may boost long‑term valuation, but short‑term dilution and cash burn could limit upside.
Earnings turnaround and acquisition could lift the stock.
Progression into the second year and planned Danish Medicines Agency discussion supports continued development momentum, but it is still pre-IND and not a clinical readout.
Milestone achievement may boost investor confidence in the company's R&D pipeline.
AlphAI scores every news story that mentions LCTX with an AI model for sentiment and relevance, and aggregates insider trades from Lineage Cell Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lineage Cell Therapeutics (LCTX) reported Q3 2026 revenue decline and wider operating loss, with non-cash warrant remeasurement affecting net income. The company acquired HUNT1 through the NeuroAirmid acquisition, extending its cash runway into Q2 2028.
Lineage Cell Therapeutics, Inc. (LCTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Acquired NeuroAirmid Therapeutics, Inc. and Its Cell Therapy Product Candidate for Huntington’s Disease, Currently Enrolling in a Phase 1b/2a Clinical Trial (REGEN4H
Lineage Cell Therapeutics (LCTX) reported Q3 2026 net income of $4.2M, reversing a $29.8M loss from Q3 2025. The company attributed the improvement to non-cash warrant remeasurement. Lineage also acquired NeuroAirmid, adding the clinical-stage HUNT1 to its pipeline. The acquisition expands Lineage's clinical-stage pipeline, with key catalysts including HUNT1 development and COR1 preclinical data expected in Q1 2027.
Lineage Cell Therapeutics (LCTX) advanced its hearing loss therapy, ReSonance, into the second year of a collaboration with William Demant Invest (WDI). The first year's milestones were completed, including manufacturing and technology transfer. WDI agreed to fund up to $12M over three years. Lineage plans to meet with the Danish Medicines Agency in Q4 2026 for scientific advice. The therapy targets severe-to-profound sensorineural hearing loss.
Lineage Cell Therapeutics (LCTX) announced its ReSonance (ANP1) program advanced to year two after meeting year-one milestones, including producing a cGMP batch and establishing a preclinical model, as approved by its Joint Scientific Committee.
Lineage Cell Therapeutics (LCTX) reported Q2 2026 cash and marketable securities of $50.8M, expected to fund operations into Q3 2028. Total revenues were $1.1M, down from $2.8M in Q2 2025. Net income was $1.5M due to a $9.4M noncash warrant gain. OpRegen GAlette sites rose to 17; ILT1 and COR1 advanced.
Lineage Cell Therapeutics, Inc. (LCTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 • Announced Progress with Wholly-Owned Corneal
Lineage Cell Therapeutics, Inc. (LCTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0000876343 0000876343 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2
Lineage Cell Therapeutics announced 3-year results from a Phase 1/2a study of OpRegen, an allogeneic cell therapy for geographic atrophy (GA) secondary to age-related macular degeneration. The data, presented at the Foundation Fighting Blindness Retinal Innovation Summit 2026, showed sustained gains in best corrected visual acuity (BCVA) and partial restoration of outer retinal structure, with benefits lasting at least three years after a single administration. These findings suggest OpRegen could stabilize and even improve GA, a condition previously considered irreversible, especially in patients with extensive treatment coverage.
The price target for Lineage Cell Therapeutics (LCTX) has been increased by 20.00% to $5.10. This adjustment reflects an updated outlook for the company's valuation.
